708274-46-8

Usage

Uses

Used in Pharmaceutical Industry:
1-Pyrrolidinecarboxylicacid,4-amino-2-methyl-,1,1-dimethylethylester,(2S,4R)-(9CI) is used as a muscle relaxant and antispastic agent for the treatment of muscle symptoms caused by neurological disorders such as multiple sclerosis, spinal cord injury, or other conditions. It is effective in reducing muscle spasms and improving mobility due to its action on GABA receptors.
Used in Neurological Treatments:
In the field of neurology, 1-Pyrrolidinecarboxylicacid,4-amino-2-methyl-,1,1-dimethylethylester,(2S,4R)-(9CI) is utilized as a therapeutic agent for managing spasticity and muscle stiffness associated with various neurological conditions. Its ability to modulate nerve activity through GABA receptors makes it a valuable treatment option for patients with limited mobility and muscle control.
Common side effects of 1-Pyrrolidinecarboxylicacid,4-amino-2-methyl-,1,1-dimethylethylester,(2S,4R)-(9CI) include drowsiness, dizziness, and weakness. It is available in both oral and intrathecal forms, allowing for flexible administration options based on the patient's needs and the severity of their condition.

Upstream product

• 477293-60-0 (2S,4S)-4-hydroxy-2-methylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 134441-72-8 1,1-dimethylethyl (2R,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-(hydroxymethyl)-1-pyrrolidinecarboxylate 
• 3398-22-9 trans-4-hydroxyproline 
• 178962-09-9 methyl (2R,4S)-4-hydroxypyrrolidine-2-carboxylate 
• 135042-17-0 (2R,4S)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 1123305-81-6 tert-butyl (2S,4S)-2-methyl-4-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate 
• 924907-62-0 1,1-dimethylethyl (2R,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-{[(methylsulfonyl)oxy]methyl}-1-pyrrolidinecarboxylate 
• 1123305-80-5 1,1-dimethylethyl (2S,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-methyl-1-pyrrolidinecarboxylate 
• 791602-89-6 4-(tert-butyldimethylsilanyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 708274-45-7 1,2-dimethylethyl-(2S,4R)-4-azido-2-methyl-1-pyrrolidinecarboxylate 

Downstream Products

• 1123305-82-7 1,1-dimethylethyl (2S,4R)-4-{[(2,5-dibromophenyl)sulfonyl]amino}-2-methyl-1-pyrrolidinecarboxylate 
• 1123306-75-1 C₁₆H₂₁Br₂FN₂O₄S 
• 1123305-83-8 1,1-dimethylethyl (2S,4R)-4-{[(2,5-dichlorophenyl)sulfonyl]amino}-2-methyl-1-pyrrolidinecarboxylate 
• 1123306-70-6 1,1-dimethylethyl (2S,4R)-2-methyl-4-({[3-(trifluoromethyl)phenyl]sulfonyl}amino)-1-pyrrolidinecarboxylate 
• 1123305-84-9 1,1-dimethylethyl (2S,4R)-4-({[2,5-bis(methyloxy)phenyl]sulfonyl}amino)-2-methyl-1-pyrrolidinecarboxylate 
• 1123306-69-3 1,1-dimethylethyl (2S,4R)-4-{[(2,5-dimethylphenyl)sulfonyl]amino}-2-methyl-1-pyrrolidinecarboxylate 
• 1123306-68-2 1,1-dimethylethyl (2S,4R)-4-({[5-chloro-2-(methyloxy)phenyl]sulfonyl}amino)-2-methyl-1-pyrrolidinecarboxylate 
• 1123305-90-7 1,1-dimethylethyl (2S,4R)-2-methyl-4-{[(2,4,5-trifluorophenyl)sulfonyl]amino}-1-pyrrolidinecarboxylate 
• 1123305-89-4 1,1-dimethylethyl (2S,4R)-4-{[(5-bromo-2,4-difluorophenyl)sulfonyl]amino}-2-methyl-1-pyrrolidinecarboxylate 
• 1123309-51-2 C₁₆H₂₁Cl₂FN₂O₄S 
• 1123309-50-1 C₁₆H₂₁BrClFN₂O₄S 
• 1123306-52-4 1,1-dimethylethyl (2S,4R)-4-{[(2,5-dibromo-3,6-difluorophenyl)sulfonyl]amino}-2-methyl-1-pyrrolidinecarboxylate 
• 1123307-53-8 2,5-dibromo-N-[(3R,5S)-1-cyano-5-methyl-3-pyrrolidinyl]benzenesulfonamide 

Relevant academic research and scientific papers

Discovery of novel cyanamide-based inhibitors of cathepsin C

The discovery of potent and selective cyanamide-based inhibitors of the cysteine protease cathepsin C is detailed. Optimization of the template with regard to plasma stability led to the identification of compound 17, a potent cathepsin C inhibitor with excellent selectivity over other cathepsins and potent in vivo activity in a cigarette smoke mouse model.

NOVEL CATHEPSIN C INHIBITORS AND THEIR USE

The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated